Cambridge Investment Research Advisors, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 19,968 shares of CPRX stock, worth $506,388. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,968Holding current value
$506,388% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$474 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$215 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$140 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$86.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$79.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.61B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...